A Study of Rituximab Versus Iodine I 131 Tositumomab Therapy for Patients With Non-Hodgkin's Lymphoma
- Conditions
- Non-Hodgkin's Lymphoma
- First Posted Date
- 2004-03-03
- Last Posted Date
- 2005-11-09
- Lead Sponsor
- Corixa Corporation
- Target Recruit Count
- 506
- Registration Number
- NCT00078598
- Locations
- ๐บ๐ธ
Medical Oncology/Hematology Associates, Dayton, Ohio, United States
๐บ๐ธMadigan Army Medical Center, Tacoma, Washington, United States
๐บ๐ธSt Mary Medical Center/Regional Cancer Center, Walla Walla, Washington, United States
Safety and Immunogenicity of Recombinant DNA and Adenovirus Expressing L523S Protein in Early Stage Non-Small Cell Lung Cancer
- Conditions
- Non-Small Cell Lung Cancer
- First Posted Date
- 2003-06-19
- Last Posted Date
- 2006-12-06
- Lead Sponsor
- Corixa Corporation
- Target Recruit Count
- 9
- Registration Number
- NCT00062907
- Locations
- ๐บ๐ธ
Cancer Care Northwest, Spokane, Washington, United States
๐บ๐ธCancer Centers of Florida, Ocoee, Florida, United States
๐บ๐ธMary Crowley Medical Research Clinic, Dallas, Texas, United States
Expanded Access Study of Iodine-131 Anti-B1 Antibody
- Conditions
- Non-Hodgkin's Lymphoma
- First Posted Date
- 2001-08-20
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Corixa Corporation
- Registration Number
- NCT00022958
- Locations
- ๐บ๐ธ
Central Recruiting Information, South San Francisco, California, United States
Safety and Efficacy of Iodine-131 Anti-B1 Antibody for Intermediate Grade Non-Hodgkin's Lymphoma Following First Line CHOP
- Conditions
- Non-Hodgkin's Lymphoma
- First Posted Date
- 2001-08-20
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Corixa Corporation
- Registration Number
- NCT00022932
- Locations
- ๐บ๐ธ
Tufts New England Medical Center, Boston, Massachusetts, United States
๐บ๐ธCornell Medical Center, New York, New York, United States
๐บ๐ธRush Medical Center, Chicago, Illinois, United States
Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody Plus CHOP For Untreated Mantle Cell Lymphoma
- Conditions
- Mantle Cell Lymphoma
- First Posted Date
- 2001-08-20
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Corixa Corporation
- Registration Number
- NCT00022945
- Locations
- ๐บ๐ธ
Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
๐บ๐ธMemorial Sloan-Kettering Cancer Center, New York, New York, United States
๐บ๐ธRush-Presbyterian-St. Lukes Medical Center, Chicago, Illinois, United States
Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody for Chronic Lymphocytic Leukemia
- Conditions
- Chronic Lymphocytic Leukemia
- First Posted Date
- 2001-08-17
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Corixa Corporation
- Target Recruit Count
- 30
- Registration Number
- NCT00022880
- Locations
- ๐บ๐ธ
Stanford University Medical Center, Palo Alto, California, United States
๐บ๐ธLong Island Jewish Medical Center, New Hyde Park, New York, United States
Safety and Efficacy of Iodine-131 Anti-B1 Antibody for NHL Patients With Greater Than 25% Bone Marrow Involvement
- Conditions
- Non-Hodgkin's Lymphoma
- First Posted Date
- 2001-08-17
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Corixa Corporation
- Target Recruit Count
- 24
- Registration Number
- NCT00022906
- Locations
- ๐บ๐ธ
Cornell Medical Center, New York, New York, United States
Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody for the Retreatment of Patients With Non-Hodgkin's Lymphoma
- Conditions
- Non-Hodgkin's Lymphoma
- First Posted Date
- 2001-08-17
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Corixa Corporation
- Registration Number
- NCT00022893
- Locations
- ๐บ๐ธ
Stanford University Medical Center, Palo Alto, California, United States
๐บ๐ธUniversity of Michigan Cancer & Geriatric Center, Ann Arbor, Michigan, United States
๐ฌ๐งChristie Hospital NHS Trust, Manchester, United Kingdom